Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02657330 · ClinicalTrials.gov registry record · Phase 1
Study of SBP-101 in Pancreatic Cancer
A Phase 1 study, sponsored by Panbela Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT02657330 is a Phase 1 study that has completed, run by Panbela Therapeutics. The registered enrollment target is 29 participants.
The verdict
NCT02657330, a Phase 1 study, has completed, sponsored by Panbela Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This phase 1 first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will identify the maximum tolerated dose (MTD). In addition, this study will also assess the pharmacokinetic (PK) profile and preliminary efficacy of SBP-101.
Interventions
- DRUG SBP-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02657330
The ClinicalTrials.gov registry entry for NCT02657330 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Panbela Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SBP-101 is the first listed.
NCT02657330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02657330 about?
NCT02657330 is a clinical study titled "Study of SBP-101 in Pancreatic Cancer". This phase 1 first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will identify the maximum tolerated dose (MTD). In addition, this study will also assess the pharmacokinetic (PK) profile and preliminary efficacy o...
What is the current status of trial NCT02657330?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2016-01. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02657330?
The interventions under investigation include: SBP-101 (DRUG).
Who is sponsoring clinical trial NCT02657330?
This trial is sponsored by Panbela Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.